{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:18:30Z","timestamp":1777483110020,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":4049,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1093\/annonc\/mdn391","type":"journal-article","created":{"date-parts":[[2008,6,15]],"date-time":"2008-06-15T00:14:13Z","timestamp":1213488853000},"page":"1915-1920","source":"Crossref","is-referenced-by-count":7,"title":["Analysis of factors influencing inclusion of 102 patients with stage III\/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy"],"prefix":"10.1016","volume":"19","author":[{"given":"I.","family":"Biasoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Franchi-Rezgui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Sibon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bri\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"de Kerviler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gisselbrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Brice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 9","key":"10.1093\/annonc\/mdn391_bb0010","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/annonc\/mdm297","article-title":"Early, intermediate and advanced Hodgkin's lymphoma: modern treatment strategies","volume":"18","author":"Diehl","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdn391_bb0015","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","article-title":"Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial","volume":"21","author":"Duggan","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn391_bb0020","first-page":"2246","article-title":"Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'etudes des lymphomes de l'Adulte H89 trial","volume":"95","author":"Ferme","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn391_bb0025","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdn391_bb0030","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/cncr.21613","article-title":"Factors influencing inclusion of patients with malignancies in clinical trials","volume":"106","author":"Tournoux","year":"2006","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdn391_bb0035","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1200\/JCO.2003.03.186","article-title":"Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials","volume":"21","author":"Mengis","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn391_bb0040","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1200\/JCO.2004.01.187","article-title":"Why cancer patients enter randomized clinical trials: exploring the factors that influence their decision","volume":"22","author":"Wright","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn391_bb0045","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1200\/JCO.2005.03.8976","article-title":"Factors associated with participation in breast cancer treatment clinical trials","volume":"24","author":"Avis","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn391_bb0050","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/cncr.10864","article-title":"Factors that influence the recruitment of patients to phase III studies in oncology: the perspective of the clinical research associate","volume":"95","author":"Wright","year":"2002","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdn391_bb0055","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on advanced Hodgkin's disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdn391_bb0060","unstructured":"INSEE. Institut National de la Statistique et des \u00c9tudes \u00c9conomiques http:\/\/www.insee.fr\/fr\/nom_def_met\/nomenclatures\/naf\/nlst17.htm (4 June 2008, date last accessed)"},{"key":"10.1093\/annonc\/mdn391_bb0065","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1182\/blood-2005-11-4429","article-title":"Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin's lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)","volume":"107","author":"Ferme","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn391_bb0070","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn391_bb0075","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/annonc\/mdi367","article-title":"Non-enrolment of ovarian cancer patients in clinical trials: reasons and background","volume":"16","author":"Harter","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdn391_bb0080","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.2003.08.010","article-title":"Participation of patients 65 years of age or older in cancer clinical trials","volume":"21","author":"Lewis","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn391_bb0085","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1002\/cncr.21907","article-title":"Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants","volume":"106","author":"Elting","year":"2006","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdn391_bb0090","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1200\/JCO.2003.09.124","article-title":"Barriers to clinical trial participation by older women with breast cancer","volume":"21","author":"Kemeny","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn391_bb0095","doi-asserted-by":"crossref","first-page":"7555","DOI":"10.1200\/JCO.2005.08.138","article-title":"Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group","volume":"23","author":"Behringer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn391_bb0100","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1200\/JCO.2003.07.160","article-title":"Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group","volume":"21","author":"Josting","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn391_bb0105","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1200\/JCO.2004.01.159","article-title":"Web-based survey of fertility issues in young women with breast cancer","volume":"22","author":"Partridge","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn391_bb0110","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S0895-4356(99)00141-9","article-title":"Barriers to participation in randomised controlled trials: a systematic review","volume":"52","author":"Ross","year":"1999","journal-title":"J Clin Epidemiol"},{"key":"10.1093\/annonc\/mdn391_bb0115","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(06)70576-9","article-title":"Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors","volume":"7","author":"Mills","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdn391_bb0120","doi-asserted-by":"crossref","first-page":"9282","DOI":"10.1200\/JCO.2005.02.6245","article-title":"Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials","volume":"23","author":"Lara","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn391_bb0125","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2006-04-019901","article-title":"Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin's lymphoma with no impairment of outcome","volume":"109","author":"Dann","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn391_bb0130","doi-asserted-by":"crossref","first-page":"307a","DOI":"10.1182\/blood.V104.11.307.307","article-title":"BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9- and HD12-trials of the German Hodgkin Study Group (GHSG)","volume":"104","author":"Diehl","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn391_bb0135","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419401427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419401427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/19\/11\/1915\/508366\/mdn391.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T08:27:10Z","timestamp":1624436830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419401427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0923753419401427"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdn391","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}